These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 28002881)

  • 1. Assessing the clinical and economic impact of increasing treatment uptake in chronic hepatitis B infection using a Markov model.
    Chinnaratha MA; Kaambwa B; Woodman RJ; Fraser RJ; Wigg AJ
    J Gastroenterol Hepatol; 2017 Jul; 32(7):1370-1377. PubMed ID: 28002881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy.
    Ruggeri M; Basile M; Coretti S; Drago C; Cicchetti A
    Appl Health Econ Health Policy; 2017 Aug; 15(4):479-490. PubMed ID: 28197805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening.
    Robotin MC; Kansil M; Howard K; George J; Tipper S; Dore GJ; Levy M; Penman AG
    J Hepatol; 2009 May; 50(5):990-8. PubMed ID: 19303657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.
    Ke W; Zhang C; Liu L; Gao Y; Yao Z; Ye X; Zhou S; Yang Y
    Hepatol Int; 2016 Nov; 10(6):924-936. PubMed ID: 27271357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.
    Buti M; Brosa M; Casado MA; Rueda M; Esteban R
    J Hepatol; 2009 Oct; 51(4):640-6. PubMed ID: 19576651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom.
    Bermingham SL; Hughes R; Fenu E; Sawyer LM; Boxall E; T Kennedy P; Dusheiko G; Hill-Cawthorne G; Thomas H
    Value Health; 2015 Sep; 18(6):800-9. PubMed ID: 26409607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of antiviral treatments for HBeAg-positive chronic hepatitis B in Canada.
    He J; Bowen JM; Xie F; Goeree R
    Value Health; 2012; 15(6):894-906. PubMed ID: 22999140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection.
    Jones J; Colquitt J; Shepherd J; Harris P; Cooper K
    Health Technol Assess; 2010 May; 14 Suppl 1():23-9. PubMed ID: 20507800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China.
    Toy M; Salomon JA; Jiang H; Gui H; Wang H; Wang J; Richardus JH; Xie Q
    Hepatology; 2014 Jul; 60(1):46-55. PubMed ID: 24990105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of Antiviral Therapy for Untreated Minimally Active Chronic Hepatitis B to Prevent Liver Disease Progression.
    Lee H; Kim BK; Jang S; Ahn SH
    Clin Transl Gastroenterol; 2021 Feb; 12(2):e00299. PubMed ID: 33600103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective.
    Veldhuijzen IK; Toy M; Hahné SJ; De Wit GA; Schalm SW; de Man RA; Richardus JH
    Gastroenterology; 2010 Feb; 138(2):522-30. PubMed ID: 19879275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan.
    Sullivan SD; Veenstra DL; Chen PJ; Chang TT; Chuang WL; Tsai C; Patel K
    J Gastroenterol Hepatol; 2007 Sep; 22(9):1494-9. PubMed ID: 17716353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of screening immigrants for hepatitis B.
    Wong WW; Woo G; Jenny Heathcote E; Krahn M
    Liver Int; 2011 Sep; 31(8):1179-90. PubMed ID: 21745300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decision analysis model for hepatitis B prophylaxis one year after liver transplantation.
    Saab S; Ham MY; Stone MA; Holt C; Tong M
    Liver Transpl; 2009 Apr; 15(4):413-20. PubMed ID: 19326401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.
    Lee KK; Wu DB; Chow PY; Lee VW; Li H
    J Gastroenterol Hepatol; 2012 Jul; 27(7):1167-74. PubMed ID: 22141402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom.
    Veenstra DL; Sullivan SD; Dusheiko GM; Jacobs M; Aledort JE; Lewis G; Patel KK
    Eur J Gastroenterol Hepatol; 2007 Aug; 19(8):631-8. PubMed ID: 17625431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine.
    Almeida AM; da Silva AL; Cherchiglia ML; Andrade EI; de Oliveira GL; Acurcio Fde A
    Value Health; 2011; 14(5 Suppl 1):S24-8. PubMed ID: 21839893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries.
    Aggarwal R; Ghoshal UC; Naik SR
    Natl Med J India; 2002; 15(6):320-7. PubMed ID: 12540064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.